This valuable information will aid the development of next-generation, ATP-based NTP analogs that contain modification(s) to confer metabolic stability against ecto-nucleotidases and avoid off-target effects while maintaining cytotoxicity against cells expressing cell-surface GRP78 (e.g., cancer cells). Here, HSPA5 is linked to cancer.